美國雅培 (ABT) 2026 Q2 法說會逐字稿

內容摘要

  1. 摘要
    • Q2 營收成長 4.8%,較前兩季加速,調整後 EPS $1.31,超過指引中位數與市場預期
    • 全年營收成長指引維持 6.5%-7.5%,但上修全年 EPS 指引至 $5.45-$5.60
    • 市場反應正面,管理層強調下半年成長動能明確,盤後未見負面消息
  2. 成長動能 & 風險
    • 成長動能:
      • 營運四大主力(營養、電生理、核心檢驗、癌症診斷)下半年動能強勁
      • 新產品線推進,包括 Amulet 360、Libre Duo、TactiFlex Duo PFA 等,未來 12 個月將陸續上市
      • 癌症診斷(Cologuard)受惠於新用戶、重複用戶成長及美國癌症協會指引支持
      • 營養事業美國 WIC 合約帶動市佔回升,成人營養產品價格策略奏效,國際業務恢復成長
      • EP(電生理)Volt 2.0、TactiFlex Duo 等新品推動歐洲與美國市佔提升,預期下半年超越市場成長
    • 風險:
      • 中國核心檢驗業務受 VBP(帶量採購)影響,雖然衝擊趨緩但仍有壓力
      • CGM(連續血糖監測)業務成長暫時受限於美國與國際市場報銷進度,短期內難以精確預測加速時點
  3. 核心 KPI / 事業群
    • 總營收:Q2 成長 4.8%
    • 調整後 EPS:$1.31
    • 核心檢驗(美國):成長 7.5%,其中醫院實驗室業務成長 13%
    • 癌症診斷:成長 13%,Cologuard 用戶數與重複篩檢均超預期
    • 營養事業:Q2 銷售季增 $1.25 億,國際兒童營養成長 6.5%,美國 WIC 合約帶動市佔回升
    • EP(電生理):全球成長低雙位數,歐洲成長 20%,美國 Volt 2.0 推出帶動動能
    • 心律管理:成長 9.5%,AVEIR 應用擴大
    • 心衰竭:成長 9%,美國雙位數成長
    • 糖尿病照護(CGM):銷售超過 $20 億,成長 9.5%
  4. 財務預測
    • 全年營收成長指引維持 6.5%-7.5%
    • 全年毛利率預期提升,Q2 調整後毛利率 58%,年增 100bps
    • 全年 CapEx 未具體揭露
  5. 法人 Q&A
    • Q: 美國醫療程序量是否有下滑風險?
      A: 管理層認為目前未見下滑,核心檢驗與心臟業務需求穩健,老齡化趨勢帶動長期需求。
    • Q: 下半年營收加速信心來源與主要成長動能?
      A: 信心來自營養、電生理、核心檢驗、癌症診斷四大業務動能明確,且進入 Q3 前動能超預期。
    • Q: Libre(CGM)全球成長趨勢、報銷進度與未來展望?
      A: CGM 市場潛力大,短期成長受限於報銷進度,若美國 Type 2 報銷擴大將大幅加速成長,目前正積極準備產能擴充。
    • Q: Exact Sciences(癌症診斷)下半年成長動能與血液檢測競爭展望?
      A: 下半年成長主因 care gap program 拉動,Cologuard 新用戶與重複用戶均超預期,血液檢測將補足產品線,維持市場領導地位。
    • Q: EP(電生理)Volt 2.0、TactiFlex Duo 等新品推進下的市佔與成長展望?
      A: 預期下半年 EP 事業將超越市場成長,Volt 2.0、TactiFlex Duo 推動歐洲與美國市佔提升,明年動能可延續。

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Good morning, and thank you for standing by. Welcome to Abbott's second-quarter 2026 earnings conference call.

    早安,感謝各位撥冗等候。歡迎參加雅培 2026 年第二季財報電話會議。

  • (Operator Instructions)

    (接線員指示)

  • This call is being recorded by Abbott. With the exception of any participant's questions asked during the question-and-answer session, the entire call, including the question-and-answer session, is material copyrighted by Abbott. It cannot be recorded or rebroadcast without Abbott's expressed written permission. I would now like to introduce Mr. Mike Comilla, Vice President, Investor Relations.

    本次電話會議由雅培進行錄音。除問答環節中任何與會者提出的問題外,整場會議(包含問答環節)之內容均為雅培享有著作權之資料。未經雅培明確書面許可,不得錄音或轉播。現在我想介紹投資人關係副總裁 Mike Comilla 先生。

  • Mike Comilla - Vice President, Investor Relations

    Mike Comilla - Vice President, Investor Relations

  • Good morning, and thank you for joining us. With me today are Robert Ford, Chairman and Chief Executive Officer; and Phil Boudreau, Executive Vice President, Finance and Chief Financial Officer. Robert and Phil will provide opening remarks. Following their comments, we'll take your questions. Before we get started, statements made today may be forward-looking for purposes of the Private Securities Litigation Reform Act of 1995, including the expected financial results for 2026.

    早安,感謝各位加入我們。今天與我一同出席的有董事長暨執行長 Robert Ford,以及財務執行副總裁兼財務長 Phil Boudreau。Robert 與 Phil 將先發表開場談話。在他們的評論之後,我們將回答各位的提問。在開始之前,今天所作之陳述可能構成 1995 年《私人證券訴訟改革法》所定義的前瞻性陳述,包括 2026 年預期財務結果。

  • Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, risk factors to our annual report on Form 10-K for the year ended December 31, 2025.

    雅培提醒,這些前瞻性陳述受風險與不確定性影響,可能導致實際結果與前瞻性陳述所示有重大差異。可能影響雅培營運的經濟、競爭、政府、技術及其他因素,已於截至 2025 年 12 月 31 日止年度之 Form 10-K 年報第 1A 項「風險因素」中討論。

  • Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. On today's conference call, as in the past, non-GAAP financial measures will be used to help investors understand at its ongoing business performance. These non-GAAP financial measures are reconciled with the comparable GAAP financial measures in our earnings news release and regulatory filings from today, which are available on our website at abbott.com.

    除法律要求外,雅培不承擔因後續事件或發展而公開發布任何前瞻性陳述修訂之義務。在今天的電話會議中,如同以往,我們將使用非 GAAP 財務衡量指標,以協助投資人了解其持續性業務表現。這些非 GAAP 財務衡量指標已在我們今日發布的盈餘新聞稿與監管申報文件中,與可比較的 GAAP 財務衡量指標進行調節,相關資料可於我們網站 abbott.com 取得。

  • Note that Abbott has not provided the related GAAP financial measures on a forward-looking basis for the non-GAAP financial measures for which it is providing guidance because the company is unable to predict with reasonable certainty and without unreasonable effort, the timing and impact of certain items, which could significantly impact Abbott's results in accordance with GAAP.

    請注意,雅培未就其所提供指引之非 GAAP 財務衡量指標,在前瞻性基礎上提供相關 GAAP 財務衡量指標,因公司無法在合理確定性且不需付出不合理努力的情況下,預測某些項目的發生時點與影響;而這些項目可能依 GAAP 對雅培業績造成重大影響。

  • Unless otherwise noted, our commentary on sales growth refers to comparable sales growth. Our definition of comparable sales growth can be found on page 2 of our press release issued earlier today and a reconciliation table containing the data needed to calculate comparable sales growth can be found on pages 16 and 17.

    除非另有說明,我們對銷售成長的評論係指可比銷售成長。我們對可比銷售成長的定義載於今日稍早發布之新聞稿第 2 頁,而包含計算可比銷售成長所需資料的調節表載於第 16 與第 17 頁。

  • With that, I will now turn the call over to Robert.

    接下來,我把電話交給 Robert。

  • Robert Ford - Chairman of the Board, Chief Executive Officer

    Robert Ford - Chairman of the Board, Chief Executive Officer

  • Okay, Mike. Good morning, everyone, and thank you for joining us. Today, we issued second quarter results that included sales growth of 4.8%, which represents an acceleration compared to the previous two quarters and adjusted earnings per share of $1.31, which exceeded the midpoint of our guidance range and the consensus estimate. Considering our second quarter results, and updated outlook for the remainder of the year, we are reaffirming our full year guidance for comparable sales growth of 6.5% to 7.5% and raising our EPS guidance range to $5.45 to $5.60.

    好的,Mike。各位早安,感謝各位加入我們。今天我們公布第二季業績,包含銷售成長 4.8%,相較前兩季呈現加速;調整後每股盈餘為 1.31 美元,超過我們指引區間的中位數以及市場一致預估。綜合第二季結果與對今年剩餘期間的最新展望,我們重申全年可比銷售成長 6.5% 至 7.5% 的指引,並將 EPS 指引區間上調至 5.45 至 5.60 美元。

  • Before summarizing our second quarter results, I want to highlight a few recent pipeline achievements, including completing patient enrollment in our Tectonic coronary IVL pivotal trial, completing our FDA submission for approval of our new Amulet 360 left atrial appendage device, and obtaining CE Mark for Libre Duo, the world's first dual glucose ketone monitoring sensor designed to detect rising ketone levels and help prevent diabetic ketoacidosis. We anticipate launching these three new products, along with our TactiFlex Duo PFA catheter in the US in a steady cadence over the next 12 months.

    在總結第二季結果之前,我想先強調近期幾項研發管線的里程碑,包括完成 Tectonic 冠狀動脈 IVL 關鍵性試驗的病患收案、完成新款 Amulet 360 左心耳封堵器的 FDA 核准申請送件,以及 Libre Duo 取得 CE 認證;Libre Duo 為全球首款雙重葡萄糖與酮體監測感測器,旨在偵測酮體上升並協助預防糖尿病酮酸中毒。我們預期在未來 12 個月內,以穩定節奏推出這三項新產品,並在美國推出 TactiFlex Duo PFA 導管。

  • We also remain on track to begin patient enrollment in the fourth quarter for several important clinical trials that will support a steady cadence of future product launches and these include a balloon expandable TAVR valve, a leadless conduction system pacing device leveraging our AVEIR pacemaker, a mitral replacement valve developed following acquisition of Cephea Valve Technologies, a peripheral IVL device developed following our acquisition of CSI and a wearable continuous lactate monitoring sensor designed to reduce the risk of sepsis following discharge from hospital.

    我們也仍按計畫於第四季開始多項重要臨床試驗的病患收案,以支持未來新產品持續推出的穩定節奏;這些試驗包括:球囊擴張式 TAVR 瓣膜、運用我們 AVEIR 心律調節器的無導線傳導系統起搏裝置、在收購 Cephea Valve Technologies 後開發的二尖瓣置換瓣膜、在收購 CSI 後開發的周邊 IVL 裝置,以及可穿戴式連續乳酸監測感測器,旨在降低病患出院後發生敗血症的風險。

  • I'll now review our second quarter results in more detail before I turn the call over to Phil, and I'll start with Diagnostics. Diagnostic test results inform approximately 70% of all healthcare decisions, making testing volumes a reliable barometer of overall healthcare activity and demand. Our test volume data sourced directly from our diagnostics instruments located across the United States and around the world, continues to reflect strong and stable demand for testing. We view this as a positive indication of the durable underlying demand for healthcare, not just in the US but globally. This durable demand was evident in our Core Laboratory results this quarter, where our US business grew 7.5% and we continued our track record of strong performance across Latin America.

    在把電話交給 Phil 之前,我將更詳細回顧第二季結果,先從診斷事業開始。診斷檢測結果為約 70% 的醫療決策提供依據,使檢測量成為衡量整體醫療活動與需求的可靠指標。我們直接取自遍布美國及全球之診斷儀器的檢測量數據,持續反映出強勁且穩定的檢測需求。我們將此視為醫療保健基礎需求具韌性的正面訊號,不僅在美國,全球亦然。這種韌性需求在本季核心實驗室業務結果中表現明顯:我們的美國業務成長 7.5%,並持續在拉丁美洲維持強勁表現的紀錄。

  • In Rapid and Molecular Diagnostics, sales declined 8%, driven by the anticipated decrease in respiratory virus testing as a result of a weaker than normal season that concluded during the second quarter. In Cancer Diagnostics, sales growth of 13% was driven by mid-teens growth of Cologuard, which is benefiting from a growing base of both new and repeat Cologuard users as well as contributions to growth from our Precision Oncology and International businesses.

    在快速與分子診斷方面,銷售下滑 8%,主因為呼吸道病毒檢測量如預期下降,因本季結束的流行季較往常疲弱。在癌症診斷方面,銷售成長 13%,主要由 Cologuard 的十位數中段成長所帶動;其受惠於新用戶與回流用戶基礎擴大,以及我們精準腫瘤學與國際業務對成長的貢獻。

  • We continue to expect Cancer Diagnostics growth in the second half of the year to be higher than the first half, supported by increasing volumes from Care Gap programs, recently launched tests and continued international adoption. In May, the American Cancer Society updated its colorectal cancer screening guidelines, reaffirming Cologuard and Cologuard Plus as preferred screening options. This designation reflects Cologuard's market-leading accuracy and superior ability to detect cancer at earlier stages compared to other available tests.

    我們仍預期下半年癌症診斷的成長將高於上半年,並將受惠於 Care Gap 計畫帶動的檢測量增加、近期推出的新檢測項目,以及國際市場持續採用。5 月,美國癌症協會更新其大腸直腸癌篩檢指引,再次確認 Cologuard 與 Cologuard Plus 為優先推薦的篩檢選項。此一定位反映 Cologuard 市場領先的準確度,以及相較其他可用檢測在更早期偵測癌症的更佳能力。

  • Moving to Nutrition where sales finished slightly ahead of our expectations for the second consecutive quarter. Sales increased sequentially by $125 million, driven by improving performance in both Pediatric and Adult nutrition. In Pediatric Nutrition, our international business was the first of our Nutrition businesses to transition back to delivering positive growth, delivering growth of 6.5% in the quarter. In US Pediatric, we exited the quarter with the full benefit of recent WIC contract wins reflected in our run rate. And as a result, Abbott is now the market leader in both WIC and non-WIC segments.

    接著看營養品業務,本季銷售連續第二季略優於我們的預期。銷售較前一季增加 1.25 億美元,主要由兒科與成人營養品表現改善所帶動。在兒科營養品方面,我們的國際業務是營養品各業務中最先恢復正成長者,本季成長 6.5%。在美國兒科方面,我們在季度結束時,近期贏得的 WIC 合約已完整反映於我們的營運速率中。因此,雅培目前在 WIC 與非 WIC 兩個市場區隔皆為市占領先者。

  • In Adult Nutrition, we continue to see positive volume trends in response to the price actions implemented late last year. In the US, retail consumption of Ensure has increased double-digits compared to consumption levels exiting last year and achieved the highest year-over-year consumption growth in the past year and a half.

    在成人營養品方面,隨著去年底實施的價格調整,我們持續看到正向的銷量趨勢。在美國,Ensure 的零售消費量相較去年底退出時的水準已呈現雙位數成長,並創下過去一年半以來最高的年對年消費成長。

  • We're also making good progress in our International Adult Nutrition business where sales continue to grow sequentially and are now approaching levels similar to this time last year. We're also benefiting from sales contributions from new innovation, including new versions of Ensure that feature higher protein, lower sugar and refreshed labeling and packaging. Overall, I remain encouraged by the progress we are making and confident in our outlook for the second half of the year.

    我們在國際成人營養品業務也取得良好進展,銷售持續逐季成長,現已接近去年同期水準。我們也受惠於新創新產品帶來的銷售貢獻,包括新版本 Ensure,具備更高蛋白、更低糖分,以及更新的標示與包裝。整體而言,我對我們取得的進展仍感到鼓舞,並對下半年的展望充滿信心。

  • Turning to EPD, where we continue to deliver consistently strong performance. Sales grew 9% in the quarter, reflecting broad-based growth across our largest markets, including India, Latin America and Southeast Asia. This performance reflects the disciplined execution of our teams and the growing demand for healthcare in emerging markets. This demand is a result of evolving market dynamics, including expanding access to healthcare, aging populations and a rising need to treat both acute and chronic conditions. These structural tailwinds, combined with our broad portfolio, expanding pipeline of biosimilars and strong brand equity position EPD to sustainably deliver high single-digit sales growth.

    接著談到 EPD,我們持續交出一貫強勁的表現。本季銷售成長 9%,反映我們最大市場的廣泛成長,包括印度、拉丁美洲與東南亞。這項表現反映團隊嚴謹的執行力,以及新興市場對醫療照護日益增加的需求。這些需求源自市場動態的演變,包括醫療可近性提升、人口老化,以及對急性與慢性疾病治療需求上升。在這些結構性順風、我們廣泛的產品組合、持續擴大的生物相似藥研發管線,以及強勁的品牌資產加持下,EPD 具備可持續交付高個位數銷售成長的定位。

  • And I'll wrap up with Medical Devices, where sales grew 8.5%, growth of 8.5% in our cardiovascular device portfolio was led by low-teens growth in Electrophysiology and high single-digit growth in Rhythm Management and Heart Failure. In Electrophysiology, the second quarter marked the beginning of an acceleration in our growth trajectory. We launched our next-generation Volt PFA catheter commonly referred to as Volt 2.0 in the U.S. in May, and we expect to transition from limited market to full market release in the third quarter. Internationally, the expanding rollout of Volt and TactiFlex Duo is gaining strong traction, driving growth of more than 20% in Europe. We remain confident in our outlook for the second half of the year, including our expectation to begin outperforming the market and recapturing share.

    最後我以醫療器材作結,該業務銷售成長 8.5%;其中我們心血管器材產品組合的 8.5% 成長,主要由電生理(Electrophysiology)低十位數成長,以及節律管理(Rhythm Management)與心衰竭(Heart Failure)高個位數成長所帶動。在電生理方面,第二季標誌著我們成長軌跡開始加速。我們於 5 月在美國推出下一代 Volt PFA 導管,通常稱為 Volt 2.0,並預期第三季將由有限市場推進至全面上市。在國際市場,Volt 與 TactiFlex Duo 的擴大推廣正獲得強勁動能,帶動歐洲成長超過 20%。我們對下半年展望仍具信心,包括預期開始跑贏市場並重新奪回市占。

  • In Rhythm Management, sales grew 9.5% as we continue to expand the use of AVEIR across both the single and dual chain segments of the pacemaker market and drive broader adoption of this innovative technology internationally. In Heart Failure, growth of 9% was led by double-digit growth in the US, driven by our market-leading portfolio of heart assist devices that address both chronic and acute patient needs.

    在節律管理方面,銷售成長 9.5%,我們持續擴大 AVEIR 在心律調節器市場單腔與雙腔區隔的使用,並在國際市場推動這項創新技術更廣泛的採用。在心衰竭方面,成長 9% 主要由美國市場的雙位數成長帶動,動能來自我們市場領先的心臟輔助裝置產品組合,可同時滿足慢性與急性病患需求。

  • In Diabetes Care, continuous glucose monitoring sales exceeded $2 billion, reflecting growth of 9.5% in the quarter. In May, we secured CE Mark for Libre Duo, the world's first dual glucose ketone wearable sensor. We will begin the international rollout of Libre Duo in the fall, and we look forward to bringing this innovative new technology to the United States market after we obtain FDA approval.

    在糖尿病照護方面,連續血糖監測(CGM)銷售額超過 20 億美元,反映本季成長 9.5%。5 月,我們取得 Libre Duo 的 CE 認證,這是全球首款可同時監測葡萄糖與酮體的穿戴式雙感測器。我們將於秋季開始在國際市場推廣 Libre Duo,並期待在取得 FDA 核准後,將這項創新新技術帶入美國市場。

  • So in summary, we remain highly focused on disciplined execution each quarter. Our second quarter results represent an important building block as we move into the second half of the year. We have momentum building across the portfolio and clear line of sight to the key drivers of sales growth acceleration that are forecasted in the second half. Our continued focus on gross margin expansion gives us confidence in raising our full-year EPS guidance, and we have several new products that we anticipate launching at a steady cadence over the next 12 months.

    總結而言,我們仍高度聚焦於每一季的嚴謹執行。第二季的成果,是我們邁入下半年的重要基石。整體產品組合的動能正在累積,且我們對下半年預期的銷售成長加速之關鍵驅動因素有清晰的可視性。我們持續聚焦毛利率擴張,使我們更有信心上調全年 EPS 指引;同時,我們預期未來 12 個月將以穩定節奏推出多項新產品。

  • And now I'll turn over the call to Phil.

    接下來我把電話交給 Phil。

  • Phil Boudreau - Chief Financial Officer, Executive Vice President - Finance

    Phil Boudreau - Chief Financial Officer, Executive Vice President - Finance

  • Thanks, Robert. As Mike mentioned earlier, please note that all references to sales growth rates, unless otherwise noted, are on a comparable basis. Turning to our second quarter results, sales increased 4.8% on a comparable basis and adjusted earnings per share of $1.31 exceeded the midpoint of our guidance range and the consensus estimate. Foreign exchange had a favorable year-over-year impact of 0.8% on second quarter sales which was a slight improvement compared to our expectations at the time of our earnings call in April.

    謝謝你,Robert。如 Mike 先前提到,請注意,除非另有說明,所有銷售成長率的引用皆以可比基礎計算。回到第二季業績,在可比基礎下銷售成長 4.8%,調整後每股盈餘為 1.31 美元,高於我們指引區間的中位數以及市場一致預期。外匯對第二季銷售的年對年影響為正向 0.8%,較我們在 4 月財報電話會議時的預期略有改善。

  • Regarding other aspects of the P&L, the adjusted gross margin profile was 58.0% of sales representing an increase of 100 basis points compared to the prior year. The improvement was broad-based, reflecting favorable business mix within the legacy Abbott portfolio and from the addition of Exact Sciences, as well as the continued operational improvements and disciplined execution of our margin expansion initiatives.

    就損益表的其他面向而言,調整後毛利率為銷售額的 58.0%,較去年提升 100 個基點。此改善為廣泛性,反映既有 Abbott 產品組合中有利的業務組合、納入 Exact Sciences 的貢獻,以及我們持續的營運改善與對毛利率擴張計畫的嚴謹執行。

  • Adjusted R&D was 6.9% of sales and adjusted SG&A was 28.6% of sales. Based on current rates, we expect exchange to have a positive impact of approximately 1% on full year sales, which includes our expectation for exchange to have a negative impact approximately 1% on third quarter sales. For the third quarter, we forecast adjusted earnings per share of $1.38 to $1.46.

    調整後研發費用占銷售額 6.9%,調整後銷管費(SG&A)占銷售額 28.6%。以目前匯率水準來看,我們預期外匯對全年銷售將帶來約 1% 的正向影響,其中包含我們預期外匯對第三季銷售將帶來約 1% 的負向影響。針對第三季,我們預估調整後每股盈餘為 1.38 至 1.46 美元。

  • With that, we'll now open the call for questions.

    接著,我們現在開放提問。

  • Operator

    Operator

  • (Operator Instructions)

    (接線員指示)

  • Robert Marcus, JPMorgan.

    JPMorgan 的 Robert Marcus。

  • Robert Marcus - Analyst

    Robert Marcus - Analyst

  • Great. Good morning. Thank you very much for taking my question. Robert, if I may, two. One, a market question, one an Abbott question. And if I start with the market question, I think a theme that a lot of investors are focused on, given some of the negative pre-announcements out of the hospital sector is the potential for decelerating procedure volumes particularly in the US.

    很好。早安。非常感謝讓我提問。Robert,如果可以的話,我有兩個問題。一個是市場面的問題,一個是 Abbott 的問題。先從市場問題開始,我想許多投資人關注的一個主題是:鑑於醫院產業出現一些負面的提前預告,手術量(procedure volumes)可能放緩,特別是在美國。

  • We heard from J&J yesterday that they're not seeing any signs to that. We heard from you this morning particularly on the diagnostic volumes where you have a great view into forward-looking volumes, it sounds like you're not seeing anything. So I'd love to hear your view on the health and the forecast of procedure volumes in the US and what you're seeing and expecting.

    我們昨天聽到 J&J 表示他們沒有看到任何這方面的跡象。今天早上也聽到你們的說法,特別是在診斷檢測量方面,你們對前瞻性的量能有很好的觀察視角,聽起來你們也沒有看到任何異常。因此我很想聽聽你對美國手術量健康狀況與預測的看法:你們目前看到什麼、又預期什麼?

  • Robert Ford - Chairman of the Board, Chief Executive Officer

    Robert Ford - Chairman of the Board, Chief Executive Officer

  • Sure. Yeah, I mean, that seems to be a topic of concern for investors. I think it's less of a concern for the companies, I think at least the companies that are in the markets that we're operating. And I think there's a couple of reasons for that. I mean I think some of the concern for the decline in volumes is tied to kind of challenges with the ACA, lower enrollment rates or dis-enrollment rates in Medicaid. And I think that's a flawed assumption, Robbie, as it relates to the medtech and diagnostic space.

    當然。是的,我的意思是,這似乎確實是投資人擔心的議題。但我認為對公司而言反而沒那麼令人擔心,至少對我們所處市場中的公司是如此。我認為原因有幾點。我想部分對量能下滑的擔憂,與《平價醫療法案》(ACA)相關的挑戰、較低的投保率或 Medicaid 的退保率有關。但我認為,Robbie,就醫療科技與診斷領域而言,這是一個有瑕疵的假設。

  • If you go back to when the ACA was implemented, really it’s the pharma companies that predominantly benefited from new patients coming into the market. We didn't see that in medtech or in diagnostics. We didn't see a spike in demand when the ACA and the expansion of Medicaid happens. So I think it's logical here to assume that if we didn't see the benefit, I don't think we're going to see the downside if that truly is what's happening.

    如果回到 ACA 實施的時候,真正主要受益於新病患進入市場的是製藥公司。我們在醫療科技或診斷領域並沒有看到那樣的情況。當 ACA 與 Medicaid 擴張發生時,我們並未看到需求激增。因此我認為,既然當時我們沒有看到好處,那麼如果現在真的發生你所說的情況,我也不認為我們會看到相對應的負面影響。

  • And I think one reason for that is that it's not Medicaid that is a driver of medtech surgical procedures in the United States. It's actually Medicare. Medicare is by far the largest U.S. payer as it relates to devices. For us, it's over two-thirds of our U.S. cardio business. So I think that's one reason.

    我認為其中一個原因是,在美國,推動醫療科技手術量的並不是 Medicaid。實際上是 Medicare。就器材而言,Medicare 是美國迄今最大的支付方。對我們來說,它占我們美國心血管業務的三分之二以上。所以我認為這是其中一個原因。

  • The other reason that I believe it's not a concern, at least right now not seeing it, is that not all healthcare products are the same here, right. So demand for say, high acuity life-saving products is very inelastic. In the US, we treat people with serious acute medical conditions and the system doesn't save lives of only those people with insurance, right. And that's why we didn't see the impact of expansion of ACA and Medicaid into the business because those patients were already being treated. And then if you look at our portfolio, it's really tied and maybe this is a little bit more of an Abbott side, we're really tied to a lot of major chronic conditions like diabetes, cardiovascular, cancer, and this is less likely to forgo insurance. So I think that's one reason.

    我認為另一個原因是,至少就目前而言,我不覺得這是個問題、也沒有看到這種情況,因為並非所有醫療產品都一樣,對吧。例如對高急重症、救命型產品的需求彈性非常低。在美國,我們治療的是嚴重的急性醫療狀況,而醫療體系不會只拯救有保險的人,對吧。這也是為什麼 ACA 與 Medicaid 擴張時,我們的業務沒有受到影響,因為那些病患本來就已經在接受治療。再看我們的產品組合,這其實也更偏 Abbott 的面向,我們與許多重大慢性疾病高度相關,例如糖尿病、心血管、癌症,而這些族群較不可能選擇放棄保險。所以我認為這也是其中一個原因。

  • I think the other reason is our data is not showing that, Robbie. And I'm not referring just to our weekly sales and things like that. It's just looking ahead. I think one of the benefits of our diverse model here is that it really provides a pretty holistic view of the entire healthcare system, not just in the US but globally.

    我認為另一個原因是,我們的數據並沒有顯示那樣,Robbie。而且我指的不只是我們每週的銷售等數據。而是著眼於未來。我認為我們這個多元化模式的一個優勢在於,它確實能提供對整個醫療保健體系相當全面的視角,不僅是在美國,也包括全球。

  • And I think as you mentioned -- my prepared remarks, we look at our diagnostic business is not obviously just a great business to be in, but it also provides us, I think, forward-looking into the healthcare environment in the health care system. And our instruments are located across the world, across the country, all in the states here in the US and testing volumes in the US have held up very well. Not seeing a decline including in the states that we've seen the highest level of ACA dis-enrollment.

    而且我認為如你所提到的——在我事先準備的發言中,我們看待診斷業務,不僅顯然是一個很好的業務領域,同時我認為它也讓我們能夠以前瞻性的角度洞察醫療保健環境與醫療體系。我們的儀器遍布全球、遍布全國,在美國各州都有部署,而美國的檢測量一直維持得非常好。我們沒有看到下滑,包括在那些我們看到ACA退保率最高的州也是如此。

  • So we've gone as deep as looking at it from that perspective. Our US Core Lab business has accelerated growth in the last two quarters. Our print here is about 7.5% this quarter. But if you unpack that, we've got a couple of different segments in our US Core Lab business, Robbie, labs and then specifically hospital labs. So these are our business of selling instruments and reagents, specifically for hospital and in-hospital testing. That business was up 13% in this quarter. So I think if I look at the diagnostic system as a forward-looking barometer there. We're not seeing that.

    因此我們已經深入到從這個角度來檢視。我們的美國核心實驗室(US Core Lab)業務在過去兩個季度加速成長。本季我們的表現約為7.5%。但如果拆解來看,我們的美國核心實驗室業務有幾個不同的區塊,Robbie,包括實驗室,以及更具體的醫院實驗室。也就是我們銷售儀器與試劑的業務,特別是用於醫院及院內檢測。該業務本季成長了13%。所以如果我把診斷系統視為一個前瞻性的指標來看,我們並沒有看到那種情況。

  • We're seeing strong demand for our US cardio business. I'd argue that our US cardio business is performing better than it's ever been. And we're seeing that same similar strong stable demand internationally, both in developed and emerging markets. So I feel very good about overall healthcare markets and especially our markets.

    我們看到美國心血管(cardio)業務需求強勁。我會主張,我們的美國心血管業務表現比以往任何時候都更好。而在國際市場上,無論是已開發市場或新興市場,我們也看到同樣類似的強勁且穩定的需求。因此我對整體醫療保健市場,特別是我們所處的市場,感到非常有信心。

  • I think I said this publicly about 1 month, 1.5 months ago, I continue to believe that healthcare demand is just going to continue to accelerate as we see this aging population dynamic. I think every day in the United States, you have 10,000 people that turned 65 and age is a driving factor of healthcare. So I think this aging population is a global dynamic. And I think the demand is -- right now, we don't see it as a concern.

    我大約在1個月到1個半月前曾公開說過,我仍然相信,隨著人口老化的趨勢,我們將看到醫療保健需求持續加速。我認為在美國,每天都有10,000人滿65歲,而年齡是推動醫療保健需求的重要因素。所以我認為人口老化是全球性的趨勢。而就目前而言,我們不把需求視為一個疑慮。

  • Robert Marcus - Analyst

    Robert Marcus - Analyst

  • Well, that's great to hear it. Maybe just a quick follow-up. One Abbott-specific. It was good to see a small beat on organic sales in second quarter. The forecast includes an acceleration in third and fourth quarter. Just -- I would love to hear how you're feeling about the confidence level and that acceleration in the second half? And if you don't mind just highlighting some of the key growth drivers that get you there. Thanks a lot.

    嗯,聽到這個很棒。也許再快速追問一下。一個是Abbott特定的。很高興看到第二季有機銷售小幅超預期。你們的預測包含第三與第四季加速。我很想聽聽你對下半年加速的信心程度如何?如果不介意,也請你重點說明一下能帶動你們達成的幾個主要成長驅動因素。非常感謝。

  • Robert Ford - Chairman of the Board, Chief Executive Officer

    Robert Ford - Chairman of the Board, Chief Executive Officer

  • Sure. Well, I'm feeling very confident, as I've said, but that feeling of confidence is really driven by a lot of hard work that the team is doing. I think Q2 results showed that we've got momentum that's building. Our growth rate stepped up to mid-single digits from where it was in the last two quarters of low single digits. Sales dollars, sales growth rate, all of that accelerated each month during the quarter.

    當然。如我所說,我感到非常有信心,但這份信心其實是由團隊大量的辛勤工作所驅動。我認為第二季的結果顯示,我們正在累積動能。我們的成長率從前兩個季度的低個位數,提升到中個位數。銷售金額、銷售成長率等各項指標,在季度內每個月都在加速。

  • So as you look to the second half, you've got a lot of businesses, I'm sure we're going to touch on a lot of them here, but a lot of the businesses that are doing strong growth rates, and we forecast and continue to do those strong growth rates. But the lift in the second half, 80% of that lift, I'm going to call it trajectory shift is really coming from four areas: Nutrition, Electrophysiology, Core Lab and Cancer Diagnostics. And each of these four businesses are entering with a lot of momentum and line of sight to the drivers of the business.

    因此展望下半年,你會看到很多業務——我相信我們在這裡會談到其中不少——有許多業務正以強勁的成長率表現,而我們也預測並將持續維持這些強勁的成長率。但下半年的拉升,其中80%——我稱之為成長軌跡的轉折——主要來自四個領域:營養(Nutrition)、電生理(Electrophysiology)、核心實驗室(Core Lab)以及癌症診斷(Cancer Diagnostics)。而這四項業務各自都帶著很強的動能進入下半年,並且對業務驅動因素有清晰的可見度。

  • And I'm sure we'll touch -- double click on and all of them during the call here. But listen, Nutrition is tracking slightly ahead of expectations. Several of our strategies, whether it's pricing, new product launches, commercial execution, that's all being done very well by the team.

    我相信我們在這通電話中也會逐一深入談到它們。不過先說,營養業務的進度略優於預期。我們的多項策略,不論是定價、新產品上市、商業執行,團隊都做得非常到位。

  • In EP, we've got a lot of great launch activity, a lot of good feedback on our new products. So I expect the second half of the market to really show that growth acceleration that we've been forecasting.

    在電生理(EP)方面,我們有很多很棒的上市活動,市場對我們新產品的回饋也很好。因此我預期下半年市場將真正展現出我們先前預測的那種成長加速。

  • In our Core Lab business, listen, our businesses have performed very well across the world. We obviously had the challenge of the VBP in China, where we had a pretty sizable portion of our international business declined for at least five quarters, around 30%. We're still forecasting a decline in the China business, but much, much lower mid-single digits. So that allows some of the other businesses that have continued to do very well and actually accelerate to kind of overpower that China impact.

    在核心實驗室業務方面,我們的業務在全球各地表現都非常好。我們顯然在中國面臨VBP的挑戰,這使得我們相當大一部分的國際業務至少連續五個季度下滑,約30%。我們仍預測中國業務會下滑,但幅度將大幅收斂至中個位數的較低水準。因此,其他持續表現非常好、甚至加速成長的業務,就能在某種程度上抵消中國的影響。

  • And then Cancer Diagnostics, very good trajectory there, especially with new Cologuard users. They're exceeding our expectations. And I've learned a lot about these Care Gap programs. I got confidence in them. We've got a lot of work around them. And so I'm confident in that.

    接著是癌症診斷,成長軌跡非常好,尤其是新的Cologuard使用者。他們的表現超出我們的預期。而且我也對這些「照護缺口」(Care Gap)計畫學到了很多。我對它們有信心。我們也在這方面投入了大量工作。所以我對此很有信心。

  • So it's really those four businesses that represent significant shift. Obviously, all the other businesses have got to continue to do well, and they've got all their strategies. But if I were to kind of really focus on what's going to drive that second half, it's these four areas here. And they're actually going into Q3 with a lot of good momentum, some of them are a little bit ahead of what we thought we would be at. So we feel good about that second quarter acceleration.

    所以真正代表顯著轉變的是這四項業務。當然,其他所有業務也必須持續表現良好,而且它們各自都有其策略。但如果我要聚焦在下半年將由什麼來驅動,就是這四個領域。而且它們在進入第三季時動能非常不錯,其中一些甚至略微領先於我們原先的預期。因此我們對第二季的加速感到樂觀。

  • Robert Marcus - Analyst

    Robert Marcus - Analyst

  • Great. Thanks for taking the questions.

    很好。謝謝你回答問題。

  • Operator

    Operator

  • Larry Biegelsen, Wells Fargo.

    Wells Fargo的Larry Biegelsen。

  • Larry Biegelsen - Analyst

    Larry Biegelsen - Analyst

  • Good morning. Thanks for taking the question. So Robert, I'd love to double-click on Libre. If you could talk about the Libre trends in the US and international. I think you only reported worldwide growth of 9.5%. What's the outlook for the CGM business, the remainder of this year? And what's your latest thinking on the US timing for the dual ketone glucose sensor and type 2 non-insulin coverage? And just lastly, can these accelerate your CGM growth or just maintain the current rate? Thank you.

    早安。謝謝你接受提問。Robert,我想更深入談談Libre。你能否談談Libre在美國與國際市場的趨勢?我想你們只公布了全球9.5%的成長。今年剩餘時間CGM業務的展望如何?以及你對美國雙酮體-葡萄糖感測器的時程、以及第二型糖尿病非胰島素使用者的給付覆蓋,你最新的看法是什麼?最後,這些因素能加速你們的CGM成長,還是只能維持目前的成長速度?謝謝。

  • Robert Ford - Chairman of the Board, Chief Executive Officer

    Robert Ford - Chairman of the Board, Chief Executive Officer

  • Sure, Larry. I love your characterization of only 9.5% on a $2 billion quarterly business. But I get where you're coming from because we've had higher growth rates. So I get that. I understand that. Let me see if I can unpack this a little bit, so we can kind of all get centered around this very important market of ours and how we see it. I'll get to all your questions, but let me just kind of talk about this, and I've said this a couple of times on other earnings calls. We remain very bullish about this market, Larry.

    當然,Larry。我很喜歡你把一家每季 20 億美元規模的業務、成長只有 9.5% 這樣來形容。但我理解你的出發點,因為我們過去的成長率更高。所以我懂。我理解。我看看能不能把這件事稍微拆解一下,讓我們大家能夠把焦點放回到這個對我們非常重要的市場,以及我們如何看待它。我會回答你所有問題,但先讓我談談這點;我在其他幾次法說會上也提過幾次。我們仍然非常看多這個市場,Larry。

  • As I've said in the past, you've got 75 to 80 million people around the world that could realistically be on a CGM, and you've only got 15 million so far. So there's still plenty of opportunity for growth, and growth acceleration. And I think it's very sustainable.

    如我過去所說,全球大約有 7,500 萬到 8,000 萬人,實際上很可能適合使用 CGM,但目前只有 1,500 萬人使用。所以仍然有很大的成長空間,以及成長加速的空間。而且我認為這是非常可持續的。

  • There's a lot of building blocks to be able to unlock that opportunity. I'd say the number one or the one that we've seen that has the most immediate impact and pretty significant to unlocking these opportunities is really reimbursement expansion. And we have a lot of reimbursement expansion opportunities in the funnel. We're in active discussions with a dozen or so countries that are either looking to introduce or to expand reimbursement.

    要解鎖這個機會,有很多基礎要件。我會說第一名、或是我們看到對解鎖這些機會最具立即影響、而且影響相當顯著的,確實是給付擴大。而我們在管線中有很多給付擴大的機會。我們正與大約十來個國家進行積極討論,這些國家不是在考慮導入給付,就是在考慮擴大給付。

  • And the reason we're having these discussions to expand or introduce these categories or expand the category is because of the robust clinical data that's been developed over a decade with this technology that supports widespread adoption. We've generated data that shows that our competitor has invested and generated data that supports that. And the data is pretty resounding. It lowers A1cs. It reduces hospitalizations. People spend more hours per day in a normal glycemic range and that has measurable outcome discussions to the healthcare system.

    而我們之所以在討論擴大或導入這些類別、或擴大類別範圍,是因為這項技術在過去十年累積了強而有力的臨床數據,支持其廣泛採用。我們已產出數據;我們的競爭對手也投入並產出支持這點的數據。而這些數據相當有說服力。它能降低 A1c。它能減少住院。人們每天能在正常血糖範圍內停留更長時間,而這對醫療體系而言有可衡量的結果與效益。

  • The challenge, Larry, is actually trying to pinpoint the exact month or quarter as to when that reimbursement expansion is going to happen. Like you mentioned in the US, and we're going to be talking about that, but it's difficult to forecast that. I would actually say it's easier to forecast the conversion of an existing eligible reimbursed patient population, the penetration of the technology and how that runs than it is to try and pinpoint when these reimbursement expansions happen. And I think when you go through a period of time like that, without a major reimbursement expansion, you see this kind of market growth plateau. And when I say plateau, I'm referring to like 8%, 9% growth, which like I said, I don't think is a bad -- is not a bad growth rate. It's just not as high as what we've seen before. And to your point on does it -- do these things keep you at this growth rate? Or does it accelerate? It drastically accelerates it, right. Like any one of these markets that goes to reimburse and expansion or introduction of reimbursement it dramatically accelerates the growth rate as we've seen in the past, Larry, and you've accompanied this segment, that has significant impact.

    Larry,挑戰其實在於要精準鎖定給付擴大會發生在確切的哪一個月或哪一季。就像你提到美國一樣,我們也會談到,但這很難預測。我反而會說,去預測既有、符合資格且已可給付的病患族群之轉換、技術滲透率以及其推進節奏,會比精準預測這些給付擴大何時發生更容易。而我認為當你經歷一段時間、沒有重大給付擴大的時候,就會看到市場成長出現這種平台期。我說的平台期,是指像 8%、9% 的成長;如我所說,我不認為這是不好——這不是不好的成長率。只是它沒有我們之前看到的那麼高。而針對你提到的:這些因素是否會讓你維持在這個成長率?還是會加速?它會大幅加速,對吧。就像過去我們看到的,只要任何一個市場開始給付、或擴大/導入給付,就會顯著拉升成長率;你也長期追蹤這個產業區塊,這影響非常大,Larry。

  • The challenge is not if these countries adopt it. The question is when and how to forecast it. And it's difficult for me to -- with a business of this size to try and pinpoint the exact reimbursement. But I can tell you, we are very active and in active discussions with very large markets to expand or introduce reimbursement.

    挑戰不在於這些國家會不會採用。問題在於何時採用,以及要如何預測。以這麼大規模的業務來說,要我精準指出確切的給付時間點,確實很難。但我可以告訴你,我們非常積極,並且正與一些非常大的市場就擴大或導入給付進行積極討論。

  • If I look ahead of some of the key reimbursement expansions that are coming, obviously, the US Type 2 is a huge opportunity. It's going to unlock around 10 million Medicare beneficiaries. It's going to accelerate commercial insurance coverage. This could be a multibillion-dollar opportunity, and it could happen in the fall. I just can't forecast it exactly -- when exactly it's going to happen. But when it does happen, it is going to definitely accelerate our sales, and we're planning and positioning ourselves to be in the best possible position as it relates to sales force, distribution, et cetera, to be able to capitalize on that opportunity.

    如果我往前看一些即將到來的關鍵給付擴大,顯然,美國第二型糖尿病(Type 2)是一個巨大的機會。它將解鎖約 1,000 萬名 Medicare 受益人。也會加速商業保險的涵蓋。這可能是一個數十億美元規模的機會,而且可能在秋季發生。我只是無法精準預測——到底會在何時發生。但一旦發生,肯定會加速我們的銷售;我們也正在規劃並調整自身定位,確保在銷售團隊、通路配送等方面處於最佳狀態,以便把握這個機會。

  • The international basal coverage expansion, I mean, right now, with all the work that we've done, I'd say you've got France, you've got Japan, you've got Canada that have broadly adopted this. Those are 3 markets that are in the top 10 international markets. There are another 7 markets here that are pretty significant movers, some larger than these markets that we'll have -- that we're having discussions. And given the clinical data, given the pressure from the societies and the patient populations, those are going to happen also. I just can't call it to the exact quarter.

    國際上的基礎胰島素(basal)涵蓋擴大方面,我是說,以我們目前所做的所有工作來看,我會說法國、日本、加拿大都已廣泛採用。這三個市場都在國際前十大市場之列。另外還有七個市場也會是相當重要的推動者,其中一些甚至比這些市場更大;我們正在與它們進行討論。而基於臨床數據、基於學會與病患族群的壓力,這些也會發生。我只是無法精準說到是哪一季。

  • So these reimbursement opportunities, they're going to accelerate it. And until that happens, I guess I'd say, yeah, you're at this like 8%, 9% growth rate, which on a $2 billion or approaching $10 billion business, that's not a bad business to be in. And I would say we feel so strongly about the -- about this market and the ability for this market to accelerate and continue to grow and the potential that exists that we're probably in the final stages here of planning for a fifth manufacturing facility.

    所以,這些給付機會會讓成長加速。而在那之前,我想我會說,是的,你大概就會處在像 8%、9% 的成長率;以一家 20 億美元、或接近 100 億美元規模的業務來說,這不是一個不好的生意。而我會說,我們對這個市場、對這個市場加速與持續成長的能力、以及其存在的潛力,都非常有信心;因此我們可能已進入規劃第五座製造工廠的最後階段。

  • We got our facility up, our last facility, our fourth facility, we got up and running probably in the 2024 time frame, given the trajectory that I'm seeing right now, and that's a $100 million sensor facility. We're probably going to be bumping up against capacity at that facility probably in the next couple of years. So we're already looking at our fifth facility. It will probably be a $1 billion investment that, right now, we're looking at where we're going to make that investment, whether it's going to be in the United States, internationally, if it's going to be in the United States, what state we're going to do. So we feel good about this market, Larry and we've got plenty of growth drivers here. I just go back to -- you've got 80 million people that can use this product and clinical data suggests that they should be using the product and the healthcare systems will benefit when they do use the product. And currently, we're at 15 million. So I feel very good about -- our business and about our position. Regarding -- I think you had a question about , you had a question about timing of CMS expansion. I think I answered that. And then timing on DGK in the US I'm not going to try and forecast that one either.

    我們把上一座工廠、也就是第四座工廠建起來並投產,大概是在 2024 年左右;以我目前看到的軌跡來看,我們可能在未來幾年就會接近那座工廠的產能上限。所以我們已經在看第五座工廠。它可能會是一筆 10 億美元的投資;目前我們正在評估要把這筆投資放在哪裡,是在美國、還是在海外;如果在美國,又會在哪一州。所以我們對這個市場感覺很好,Larry,而且我們有很多成長驅動因素。我還是回到——有 8,000 萬人可以使用這個產品,而臨床數據顯示他們應該使用;而當他們使用時,醫療體系也會受益。而目前我們只有 1,500 萬。所以我對——我們的業務以及我們的定位——感到非常有信心。關於——我想你有一個問題是關於,你有一個問題是關於 CMS 擴大的時點。我想我已經回答了。至於美國 DGK 的時點,我也不打算嘗試去預測。

  • But what I will say is that the discussions are in, I would call very, very advanced kind of final stages, and I'm not going to try and forecast that. As soon as we have it approved, we'll issue a press release and we'll go and start preparing the market. But we are hearing great things already from some of the European physicians that have had some early access to the product. So we feel good about that.

    但我要說的是,相關討論已進入我所稱非常、非常深入的最後階段,我不打算去預測結果。一旦獲得核准,我們就會發布新聞稿,並開始著手進行市場準備。不過,我們已經從一些曾較早接觸到該產品的歐洲醫師那裡聽到很多正面的回饋。所以我們對此感到很有信心。

  • And we got a lot of product innovation coming too, Larry. I mean I know there's a lot of focus here on DGK. We probably had two more programs that I'm not going to talk about for competitive reasons here, but that's going to be another driver of growth for us, too. So again, I feel good about this market. We're making the investments. We believe in the growth trajection the potential that exists in it, and we're full speed in execution.

    而且我們也會有很多產品創新即將推出,Larry。我的意思是,我知道大家在這裡把焦點放在 DGK 上。我們可能還有另外兩個計畫,出於競爭考量我不便在此談論,但那也將成為我們另一個成長動能。所以再次強調,我對這個市場感到樂觀。我們正在進行投資。我們相信其中存在的成長軌跡與潛力,並且正全速執行。

  • Larry Biegelsen - Analyst

    Larry Biegelsen - Analyst

  • Robert, thanks for the comprehensive answer. Just to set the record straight. I would say you only reported worldwide growth. I wasn't criticizing the 9.5%, but I just wanted to be clear about that. So -- but thank you for the comprehensive answer.

    Robert,謝謝你這麼全面的回答。只是為了釐清事實。我會說你只報告了全球成長。我不是在批評 9.5%,只是想把這點說清楚。所以——不過還是謝謝你詳盡的回答。

  • Robert Ford - Chairman of the Board, Chief Executive Officer

    Robert Ford - Chairman of the Board, Chief Executive Officer

  • [laughter] You can criticize, Larry. That's fine. We are -- this is a good business, and it's doing very well. I know it gets a lot of attention for -- because of us and the competitor. But it's a good business. There's a lot of opportunity here. I'm just trying to provide context of the opportunities and how this will accelerate given reimbursement expansions.

    [笑聲] 你可以批評,Larry。沒問題。我們——這是一門好生意,而且表現非常好。我知道它受到很多關注——因為我們以及競爭對手的關係。但這確實是一門好生意。這裡有很多機會。我只是想提供一些機會面的背景脈絡,以及在給付擴張的推動下,這將如何加速。

  • Larry Biegelsen - Analyst

    Larry Biegelsen - Analyst

  • Understood. Thank you.

    了解。謝謝。

  • Operator

    Operator

  • Vijay Kumar, Evercore ISI.

    Vijay Kumar,Evercore ISI。

  • Vijay Kumar - Equity Analyst

    Vijay Kumar - Equity Analyst

  • Hi, Robert. Good morning, and thanks for taking the question. Hey, I want to dive a little bit on Exact Sciences. Business did, to your point, slightly north of 13%. I think you're assuming a step-up in back half, maybe 16%, 16%-plus. And a lot of that is driven -- maybe some of that is pricing, some of it is Care Gap. So my question is, how much visibility do you have on these Care Gap programs in the back half stepping up for Exact Sciences.

    嗨,Robert。早安,謝謝讓我提問。我想更深入談一下 Exact Sciences。如你所說,上半年業務成長略高於 13%。我想你假設下半年會加速,可能到 16%、16% 以上。而其中很大一部分是由——也許部分來自定價,部分來自 Care Gap。所以我的問題是,對於下半年 Exact Sciences 的這些 Care Gap 計畫加速,你有多少能見度?

  • And I think a related question was the Freenome just present at the redo data advanced adenoma detection rate was north of 18%. I think that's well above your competition. So when you think about the blood side of CRC screening, do you still expect Abbott to be the market leader on the blood side even though your entry into the market will be slightly behind Guardant. Thank you.

    我想另一個相關問題是,Freenome 剛公布的 redo 數據中,進階腺瘤偵測率超過 18%。我認為這明顯高於你們的競爭對手。所以當你思考結直腸癌(CRC)篩檢的血液檢測端時,即使你們進入市場的時間會略晚於 Guardant,你仍然預期 Abbott 會成為血液端的市場領導者嗎?謝謝。

  • Robert Ford - Chairman of the Board, Chief Executive Officer

    Robert Ford - Chairman of the Board, Chief Executive Officer

  • Sure. Yeah, we grew 13% in the first half. Our deal model that we put together to support the acquisition for 2026 at mid-teens, I feel confident that we'll achieve that. The model called for second half being higher than first half. The integration is going very good, very well. We're not seeing any kind of issues or disruption. I'm just very impressed by the team there and their understanding of the market and they've done a good job here at making sure that I understand all the different detailed kind of elements of how this market works and drives.

    當然。是的,我們上半年成長 13%。我們為支持這項收購而建立的交易模型,對 2026 年的假設是中段十位數成長(mid-teens),我有信心我們能達成。模型預期下半年會高於上半年。整合進展非常順利。我們沒有看到任何問題或干擾。我對那邊的團隊印象非常深刻,他們對市場的理解很到位,也很努力確保我能理解這個市場如何運作與驅動的各種細節要素。

  • To your point of the Care Gap, volumes ramp in the second half. And that's what's going to help drive. It's not just that, but it's a contributing factor to the acceleration in the second half. Care Gap programs really are they help the health systems achieve their HEDIS credit, their CMR Star ratings. And that focus from the healthcare systems for some reason, tends to happen in the second half. So they're looking at their scores, they're looking at their ratings and they're looking at ways at how they can ensure that they're achieving their targets. That seems to happen a lot in the second half.

    就你提到的 Care Gap 而言,量能會在下半年爬升。而這將有助於帶動成長。不僅如此,但它確實是下半年加速的一個促成因素。Care Gap 計畫的本質是協助醫療體系取得其 HEDIS 認列、以及其 CMR 星級評等(Star ratings)。而醫療體系對這件事的重視,不知為何往往會集中在下半年。所以他們會檢視自己的分數、檢視評等,並尋找方法以確保達成目標。這種情況在下半年特別常見。

  • Do we have visibility? Yeah, we absolutely have visibility. We have -- the team is an incredible team there in terms of their Market Access team. They've got work to do, there's no doubt, but there's a lot of visibility to those programs, and there's a lot of conversations that are happening with the health systems. They're seeing a need to continue to push on earlier detection with Cologuard.

    我們有能見度嗎?有,我們絕對有能見度。他們的團隊——尤其是市場准入(Market Access)團隊——非常強。他們確實還有工作要做,這點毫無疑問,但對這些計畫的能見度很高,而且與醫療體系之間正在進行大量對話。他們看到了持續推動以 Cologuard 進行更早期偵測的需求。

  • So I feel good about the ramp-up of the Care Gap and the visibility to that. You mentioned price being an element there. So as we transition from Cologuard to Cologuard Plus, that's a little bit of a tailwind also. But I think there are a lot of key growth drivers here in the medium, long term, Vijay, and they're all looking very good.

    所以我對 Care Gap 的量能爬升以及相關能見度感到樂觀。你提到價格是其中一個因素。因此,當我們從 Cologuard 轉換到 Cologuard Plus 時,這也會帶來一些順風。但我認為在中長期有很多關鍵成長驅動因素,Vijay,而且目前看起來都非常不錯。

  • If you look at the growth from Cologuard users, they're exceeding our expectations. So there's a certain forecast of how many new users we will be able to bring in, and the team are actually exceeding that target. The number of repeat users in Cologuard, we talked about the rescreen. That funnel is expanding and it is extremely reliable in terms of -- since we have the names, people want to up to date with their screening. So that rescreen funnel is expanding, and that's a great opportunity for us.

    如果你看 Cologuard 使用者帶來的成長,他們的表現超出我們的預期。我們對能帶來多少新使用者有一定的預測,而團隊實際上正超越該目標。至於 Cologuard 的重複使用者,我們談過再篩檢(rescreen)。那個漏斗正在擴大,而且在可靠性方面非常高——因為我們掌握名單,大家也希望自己的篩檢保持最新。所以再篩檢漏斗正在擴大,這對我們而言是很好的機會。

  • Obviously, Cancerguard, we're investing in that launch. We're going to be reviewing some of our next MRD-Next-generation MRD data will be coming out also. There's international expansion. I've been involved in some of the discussions around that, and we're going to be making some pretty interesting progress there with certain governments.

    當然,Cancerguard 方面,我們正在投入資源推動上市。我們也將檢視一些下一批 MRD——下一代 MRD 的數據也會陸續公布。另外還有國際擴張。我也參與了一些相關討論,我們將在與某些政府的合作上取得相當有意思的進展。

  • And then to your point, the ability to add a blood test to the portfolio is going to be, I think, extremely attractive for us. Now as you know, blood tests, they're obviously very -- a little bit more convenient. I think Cologuard is pretty convenient, but I would say blood is a little bit more convenient than that. But it has a problem, which is it doesn't have the same sensitivity as it relates to detection of precancerous polyps and an earlier-stage detection, right. And when you think about screening, that's super important.

    然後如你所說,把血液檢測加入產品組合的能力,我認為對我們會非常有吸引力。如你所知,血液檢測顯然更——更方便一些。我認為 Cologuard 已經很方便了,但我會說血液檢測比它還要更方便一點。但它有個問題,也就是在偵測癌前息肉以及更早期分期偵測方面,它的敏感度不如其他方式,對吧。而當你談到篩檢時,這點非常重要。

  • So I think we'll be the only company to say, will you be a leader in blood? I don't actually see it like that, Vijay. I -- we want to continue to be the leader as it relates to screening and now, you're going to have a company that's going to have the opportunity to not only offer best-in-class stool test, but now we'll also have best-in-class blood test.

    所以我認為我們會是唯一一家會說:你會在血液檢測方面成為領導者嗎?Vijay,我其實不這麼看。我——我們希望在篩檢領域持續保持領導地位;而現在,你將會有一家公司的機會,不僅能提供同級最佳的糞便檢測,現在也能提供同級最佳的血液檢測。

  • And I think there might be opportunities. I think as you saw some of the guidelines come up from the American Cancer Society, there is a preference and a drive towards Cologuard, but if you've got -- you still have a lot of patients that aren't up to date with their screening or haven't done screening, whether it's colonoscopy or Cologuard, and that will be an opportunity for us. So that will be a new market, and I think the way I view it is, okay, we'll bring these patients into these consumers into our screening funnel, and then we'll be able to educate them on the benefits of Cologuard.

    而且我認為可能會有一些機會。我想正如你看到美國癌症協會提出的一些指引,對 Cologuard 有偏好並且有推動力;但如果你——你仍然有很多病患的篩檢並未更新或尚未做過篩檢,不論是大腸鏡或 Cologuard,這對我們而言都會是一個機會。所以那將是一個新市場;而我看待它的方式是:好,我們把這些病患、這些消費者帶進我們的篩檢漏斗,接著我們就能教育他們 Cologuard 的效益。

  • So I think we'll be in a great position as it relates to being the only company to have both stool and blood and be able to kind of support the health systems with that. But even with that precancerous detection being lower than Cologuard doing a blood test, if you're not doing anything, it's probably a good first step, but then you want to actually start to do it with a Cologuard test.

    所以我認為,就成為唯一一家同時擁有糞便與血液檢測、並能以此支援醫療體系而言,我們會處於非常有利的位置。但即便血液檢測對癌前病變的偵測率低於 Cologuard,如果你什麼都沒做,那它可能是個不錯的第一步;但接著你會希望實際上改用 Cologuard 檢測。

  • So again, I see a lot of great opportunity in our Cancer Diagnostic business. The integration is going very well. I continue to be very impressed with this team and their understanding of the market that they've built and their plans to continue to drive it.

    所以再次強調,我在我們的癌症診斷業務上看到很多很好的機會。整合進展非常順利。我持續對這個團隊印象深刻,他們對自己建立起來的市場有很深的理解,也有持續推動成長的計畫。

  • Vijay Kumar - Equity Analyst

    Vijay Kumar - Equity Analyst

  • That's helpful, Robert. Thank you.

    這很有幫助,Robert。謝謝。

  • Operator

    Operator

  • Matt Taylor, Jefferies.

    Matt Taylor,Jefferies。

  • Matthew Taylor - Equity Analyst

    Matthew Taylor - Equity Analyst

  • Hi, good morning. Thanks for taking the question. I thought I'd be worth spending a minute on EP given you have this nice series of launches here, you seem to be gaining traction with Volt already. Could you comment on market dynamics and your aspirations in the market? Maybe just talk about how you think the AF market will continue to grow. And I know you're committing to growing above market in the second half. Could you talk about how that could continue into next year and the kind of share aspirations that you have?

    嗨,早安。謝謝讓我提問。我想值得花一點時間談談 EP,因為你們這裡有一連串很不錯的上市推出,而且你們似乎已經在 Volt 上取得進展。你能否評論一下市場動態以及你們在市場中的企圖心?也許談談你認為 AF 市場將如何持續成長。我知道你們承諾在下半年成長會高於市場。你能談談這如何延續到明年,以及你們對市占的企圖心大概是什麼嗎?

  • Robert Ford - Chairman of the Board, Chief Executive Officer

    Robert Ford - Chairman of the Board, Chief Executive Officer

  • Sure. I'm not going to give specific targets on share. I think what I'll leave it right now is, yeah, we do expect to grow faster than the market. And I think we're entering this phase here where we'll start to outperform market and capture share. I think we saw early signs of that in Q2, Matt. Sales increased every month in the quarter, very good progress there.

    當然。我不會給出具體的市占目標。我想我現在能說的是:是的,我們確實預期會比市場成長更快。而且我認為我們正進入這樣一個階段:我們將開始跑贏市場並取得市占。我想我們在第二季已經看到一些早期跡象,Matt。該季每個月的銷售都在增加,進展非常好。

  • But I think what we'll really start to see that happen in the second half as we transition from a limited market release to full market release of Volt in the US and then continue to roll out TactiFlex Duo internationally. We continue to get very great -- very good feedback from physicians and doctors around the world that are using the product. I say Volt for me, what I hear a lot about Volt is just the continued integration to the mapping system and not having to use a mapping system or a mapping infrastructure that's a little bit subpar versus where the market-leading mapping systems are.

    但我認為真正會在下半年開始更明顯,因為我們會把 Volt 在美國從有限市場釋出轉為全面市場釋出,並且持續在國際市場推進 TactiFlex Duo 的上市。我們持續收到全球使用該產品的醫師與醫生非常棒——非常好的回饋。就 Volt 而言,我聽到最多的是它與電生理標測系統的持續整合,以及不必再使用相較於市場領先標測系統而言略顯不足的標測系統或標測基礎設施。

  • So now you don't really have to take that step back a little bit. You've got a PFA catheter that's got very good map integration. Opportunity, especially here in the US, I keep hearing that for ASC and ASC adoption given the open footprint of the mapping system and the ability to do these cases with general sedation just with sedation versus general anesthesia.

    所以現在你不需要再稍微退一步。你有一支具備非常良好標測整合的 PFA 導管。特別是在美國,機會在於 ASC 以及 ASC 的採用,因為標測系統具有開放式足跡(open footprint),而且能夠在這些病例中以一般鎮靜(僅鎮靜)來進行,而不是全身麻醉。

  • So those are kind of the -- and then the ability here, given the contact, we've got to prove this out a little bit, but given the contact and integration with mapping and the visualization of that, ability to deliver better outcomes by producing more durable lesions. So Volt is getting great feedback, and we feel good now that we can move to full market release.

    所以這些算是——另外,基於接觸(contact),我們還需要再多加驗證,但基於接觸與標測整合以及其可視化能力,有機會透過形成更持久的病灶來帶來更好的治療結果。因此 Volt 得到很好的回饋,我們也對現在能推進到全面市場釋出感到有信心。

  • TactiFlex Duo, this is coming on the chassis of a very well-liked and understood catheter in the TactiFlex chassis. So that's been recognized for ease of use versatility, pretty seamless transition between PFA and RF. So seeing nice share capture trends in Europe, our EP business was up 20% in Europe in the second quarter. So that's good.

    TactiFlex Duo 是建立在一個非常受喜愛且被充分理解的導管平台之上,也就是 TactiFlex 底盤(chassis)。因此它因易用性與多功能性而受到肯定,並且在 PFA 與 RF 之間切換相當順暢。所以我們在歐洲看到不錯的市占取得趨勢;我們的 EP 業務在第二季於歐洲成長了 20%。所以這很好。

  • I have high expectations for both these catheters, but as I've been pretty clear over the last couple of years, our growth strategy is not going to be built off like one product or one catheter that we've got to kind of monitor it closely and see -- like yes, these catheters will drive a lot of growth. But we're in the -- we believe that our right growth strategy is to really focus on selling the entire procedure. And that's why we've been focusing on not just on these PFA catheters, but also on the mapping systems, all the ancillary, the diagnostics, the introducers, the ice catheter. I mean all of that matters. And that's what our focus is here is to really position ourselves as a leading company in this space.

    我對這兩支導管都有很高的期待;但正如我過去幾年一直講得很清楚,我們的成長策略不會建立在像是某一個產品或某一支導管上,然後我們必須非常密切地監控它並觀察——是的,這些導管會帶動很多成長。但我們正處於——我們相信正確的成長策略,是要真正聚焦於銷售整個手術流程(procedure)。這也是為什麼我們不只專注在這些 PFA 導管上,也同樣專注在標測系統、所有周邊耗材、診斷產品、導入鞘(introducers)、ICE 導管。我的意思是,這些都很重要。而我們在這裡的重點,就是要真正把自己定位為這個領域的領先公司。

  • And we've got a nice pipeline of PFA catheters still in the works. So between now and 2029, we'll have iterations and new versions and new ideas come out. But we're also equally investing in mapping and ensuring that our mapping superiority is maintained as obviously, competitors are launching their own mapping systems.

    而且我們仍有一個不錯的 PFA 導管產品管線正在開發中。所以從現在到 2029 年之間,我們會推出迭代版本、新版本以及新的想法。但我們也同等地投資於標測,並確保我們在標測上的優勢得以維持,因為很明顯競爭對手也正在推出他們自己的標測系統。

  • So we'll continue to invest in that also and our ability to stay ahead is, I think, is very strong. So I think from a forecast perspective, I expect global EP growth to accelerate. It's in the teens right now. It will accelerate in the second half, for sure, and outperforming the market. And I expect that momentum that we're building this year to carry through to next year.

    所以我們也會持續投資於此;而我認為我們保持領先的能力非常強。因此從預測的角度來看,我預期全球 EP 成長將會加速。目前大約在十幾%的水準。下半年肯定會加速,並且跑贏市場。而我也預期我們今年建立的這股動能會延續到明年。

  • And I think we'll get an additional boost into this EP portfolio with our new LAA device. I think feedback there has been extremely positive. And we filed with the FDA. I think here, I probably feel a little bit more comfortable saying, I can see a potential to be able to get this approved by year-end. And then with that, we'll have strong momentum going into next year with both rollout of TactiFlex Duo in the US, continued acceleration of Volt in the US, launching our next-generation LAA device also. So I see that momentum continuing into next year.

    而且我認為我們的新 LAA 裝置也會為這個 EP 產品組合帶來額外助力。我想那邊的回饋極度正面。而且我們已向 FDA 提交申請。我想在這裡,我可能比較有把握地說:我看到有可能在年底前取得核准。有了這個,我們明年將會有很強的動能:包括 TactiFlex Duo 在美國的上市推廣、Volt 在美國的持續加速,以及我們下一代 LAA 裝置的推出。所以我看到這股動能會延續到明年。

  • Matthew Taylor - Equity Analyst

    Matthew Taylor - Equity Analyst

  • Great. Thanks so much.

    太好了。非常感謝。

  • Operator

    Operator

  • Travis Steed, BofA Securities.

    Travis Steed,美國銀行證券(BofA Securities)。

  • Travis Steed - Analyst

    Travis Steed - Analyst

  • Hey, Robert. Thanks for taking the questions. I guess as we move into the second half of this year, investors are going to start looking more into next year. Just curious how you think about the Abbott portfolio in the next year. This is kind of a year that step-up for better growth, you've got easier nutrition comps, expanding coverage in Libre, you talked about EP accelerating in the next year, Amulet 360 launching at the beginning of the year. Just curious at a high level how you kind of think about the Abbott portfolio in 2027 and growth.

    嗨,Robert。謝謝你回答問題。我想隨著我們進入今年下半年,投資人會開始更關注明年。想請教你如何看待明年 Abbott 的產品組合。今年算是成長加速的一年,你們的營養品比較基期更容易、Libre 的給付覆蓋擴大、你提到 EPD 明年會加速、Amulet 360 也會在年初上市。想在高層次上請你談談你如何看待 Abbott 在 2027 年的產品組合與成長。

  • Robert Ford - Chairman of the Board, Chief Executive Officer

    Robert Ford - Chairman of the Board, Chief Executive Officer

  • Sure. I mean it's well early to give exact guidance in 2027, but listen, we have a target always of targeting high single-digit growth on the top, double-digit on the bottom. I previously referenced 7% as a very kind of sustainable growth rate. I believe 7% is still the right target despite there being a much larger base today versus where we were several years ago.

    當然。我的意思是,現在要給出 2027 年的精確指引還太早,但你知道,我們一直有一個目標:營收端鎖定高個位數成長,獲利端(EPS)鎖定雙位數成長。我之前提到 7% 是一個非常可持續的成長率。我相信即使相較幾年前,我們現在的基礎規模大得多,7% 仍然是正確的目標。

  • It's probably only -- I think I looked at this, there's only like five healthcare companies with sales over $30 billion that are growing at least 7%. So I think we have a differentiated portfolio here, a very resilient portfolio. And I think, as I said, the strategy here of what we've been doing over the last couple of quarters to get us in into that 7% top line growth rate.

    大概只有——我想我看過資料,營收超過 300 億美元且仍能至少成長 7% 的醫療保健公司,大概只有五家左右。所以我認為我們在這裡擁有一個差異化、非常具韌性的產品組合。而且我認為,如我所說,我們在過去幾個季度所做的策略,正是為了讓我們達到 7% 的營收成長率。

  • And I think it's really driven, Travis, by looking at the portfolio and in the execution. If I look at the four segments, again, I'm not providing 2027 guidance. But when I look at each one of them in their ranges, Nutrition has been a 2% to 4% grower. And I think that's probably, as we think about it going forward, that's probably the right range to be thinking about. Our diagnostics portfolio with the addition of Exact, the VBP impact in China subsiding a little bit is now a 7% to 8% kind of range that we think about.

    而我認為這真的主要來自於,Travis,對產品組合的檢視以及執行力。如果我看四個事業部門,再次強調,我不是在提供 2027 年指引。但當我看每個部門的成長區間時,營養品一直是 2% 到 4% 的成長者。而我認為,往前看,這大概就是我們應該思考的合理區間。我們的診斷業務,隨著 Exact 的加入,加上中國 VBP 的影響稍微趨緩,現在我們思考的區間大概是 7% 到 8%。

  • Our EPD business has reliably done this for like five years, like 7% to 9%. And Medtech, we view as kind of an 8% to 10% grower. So the low end of that range is around 6.5%. The high end is around 8.5%. So I think 7% is a pretty sustainable kind of growth rate going forward.

    我們的 EPD 業務在過去大約五年一直很穩定地做到 7% 到 9%。而醫療器材(Medtech)我們視為大概 8% 到 10% 的成長者。所以這些區間的低端大約是 6.5%。高端大約是 8.5%。因此我認為 7% 是一個相當可持續的長期成長率。

  • So -- and that's what we target, high single digit, double-digit EPS growth. And I think we're well positioned, executing what we're executing in the second half and the portfolio we have, I think the sustainability of that 7%. And then obviously, all the pipeline. I mean, we've got programs that we're going to start in Q4, at least from a trial perspective, that are going to start to deliver contributions in '29 and '30. So yeah, we're thinking about '27 for sure, but we're also thinking '28, '29 and 2030 and one of the things that we need to be able to kind of sustain that top line growth rate.

    所以——這就是我們的目標:營收高個位數成長、EPS 雙位數成長。我認為我們的定位很好,無論是下半年正在推進的執行工作,還是我們現有的產品組合,都支持 7% 的可持續性。然後當然還有整個研發管線。我的意思是,我們有一些計畫至少從試驗角度來看,會在第四季啟動,並在 2029、2030 年開始帶來貢獻。所以沒錯,我們當然會思考 2027,但我們也在思考 2028、2029、2030,以及我們需要做哪些事情來維持那樣的營收成長率。

  • Travis Steed - Analyst

    Travis Steed - Analyst

  • That's great. Thanks a lot.

    太好了。非常感謝。

  • Operator

    Operator

  • Josh Jennings, TD Cowen.

    Josh Jennings,TD Cowen。

  • Joshua Jennings - Analyst

    Joshua Jennings - Analyst

  • Hi, good morning. Thanks for the question. I wanted to just ask on the Structural Heart unit. I mean I think your team has been pretty clear that it may take some time for the US franchise to regain its foundation. But any help just thinking through some of the strategic initiatives, either on the commercial infrastructure side, pricing in front of some of the innovation that you've talked about, Robert, or with the balloon expandable TAVR and the mitral replacement valve that's in development?

    嗨,早安。謝謝讓我提問。我想請教結構性心臟(Structural Heart)事業部。我想你們團隊已經很清楚地表示,美國業務要重新打穩基礎可能需要一些時間。但能否協助我們理解一些策略性措施:不論是在商業基礎建設方面、在你提到的一些創新推出之前的定價策略(Robert),或是正在開發中的球囊擴張式 TAVR 與二尖瓣置換瓣膜?

  • Just help us think through when can the Structural Heart franchise start to see improved growth in trends. Is that 2027? And to your answer to one of your last questions on the 2027 outlook, I mean, maybe soft comps for '27 in Structural Heart get back in the groove next year. Thanks.

    也請幫我們思考一下,結構性心臟業務何時能開始看到成長趨勢改善。會是 2027 年嗎?另外,呼應你剛才對 2027 年展望的回答,我的意思是,也許 2027 年結構性心臟的比較基期會比較軟,明年就能回到正軌。謝謝。

  • Robert Ford - Chairman of the Board, Chief Executive Officer

    Robert Ford - Chairman of the Board, Chief Executive Officer

  • Yeah. Listen, I expect Structural Heart by the end of this year to be in that kind of mid- to high single-digit growth rate back to where we were before. I think that I've been pretty clear about where we're falling short. It's not a price issue. It's not a product issue. It's really kind of how we think about -- how we think about competing in the mitral space, specifically in the US, we've seen competitive intensity increase there, here in the US. And I mentioned that during our last earnings call, I said it was going to take us a couple of quarters, Q2 is the first one.

    是的。聽著,我預期結構性心臟到今年年底會回到我們之前的水準,也就是中到高個位數的成長率。我想我已經很清楚說明我們落後的地方。這不是價格問題。也不是產品問題。真正的問題在於我們如何思考——我們如何在二尖瓣領域競爭,特別是在美國;我們看到美國這邊的競爭強度上升。我在上次財報電話會議也提到過,我說這需要幾個季度來調整,而第二季是第一個季度。

  • But I think by the end of the year, I think you'll start to see that start to change. We've made changes. We made personnel changes. We've also looked at how we're approaching the market. It's not a pricing thing. It's just more about how we think about -- we have one of the most comprehensive and broadest portfolios in Structural Heart. And I think that our team is kind of trying to figure out a better way of how to position that full portfolio.

    但我認為到年底,你會開始看到情況出現改變。我們已經做了調整。我們做了人員變動。我們也重新檢視我們切入市場的方式。這不是定價的問題。更多是關於我們如何思考——我們在結構性心臟領域擁有最完整、最廣泛的產品組合之一。我認為我們的團隊正在嘗試找出更好的方式,來定位這個完整的產品組合。

  • We're showing good growth in Tricuspid. We've shown good growth in TAVR here in the US. We've got to do a better job in mitral. The team knows that. They're motivated. I've met with them and they're determined to respond to the challenge. So US has got some work to do. We've had a lot of work this quarter. I expect to be a lot of work in Q3, and I think you'll start to see that change in Q4.

    我們在三尖瓣(Tricuspid)方面展現了不錯的成長。我們在美國的 TAVR 也展現了不錯的成長。我們必須在二尖瓣(mitral)做得更好。團隊知道這點。他們很有動力。我也和他們見過面,他們決心回應這個挑戰。所以美國這邊還有一些工作要做。我們這一季做了很多工作。我預期第三季也會有很多工作,而我認為你會在第四季開始看到改變。

  • I will put a plug-in for the international team. I think the international team has been able to grow double digits in the first half. TAVR was up 30% in the first half, MitraClip and TriClip and our structural interventions portfolio. I mean all of that has grown really strong, so that international team has done a really good job, and there are things that the US organization can learn from some of the strategies that have been developed there.

    我也要替國際團隊說句話。我認為國際團隊在上半年做到了雙位數成長。上半年 TAVR 成長了 30%,MitraClip、TriClip 以及我們的結構性介入產品組合也都成長得非常強勁。所以國際團隊做得非常好,而美國組織也可以從那邊發展出的某些策略中學到一些東西。

  • So work to be done there. But I still think that this is probably one of our key growth drivers. If you think about the pipeline that we're assembling, you've got a lot of -- you've got guideline changes, you've got product launches. We just launched TriClip in Japan. Label expansions, pipeline, I think Cephea going into trial, I continue to just only hear incredibly positive things about this mitral valve replacement.

    所以那裡還有一些工作要做。但我仍然認為,這很可能是我們的關鍵成長驅動因素之一。如果你想想我們正在組建的產品管線,你會看到很多——你有指引變更,你有產品上市。我們剛在日本推出 TriClip。適應症標籤擴增、產品管線,我認為 Cephea 正在進入試驗;而關於這項二尖瓣置換,我持續只聽到極其正面的回饋。

  • I think we have the potential to live up to the promise that we thought maybe a decade ago in 2015 when everybody was making investments in mitral believe that it could be just as big as TAVR. I actually think now with this product, we have the potential to actually make that a reality.

    我認為我們有潛力兌現我們大約十年前、也就是 2015 年時的承諾;當時大家都在二尖瓣領域投資,並相信它可能會和 TAVR 一樣大。我其實認為,現在有了這個產品,我們有潛力把那件事真正變成現實。

  • So we've got a lot of momentum here. And I think in the short term, we're dealing with some improved commercial execution that we've got to do. And I've got trust and confidence in the team that they know what they've got to do and they'll deliver.

    所以我們在這裡有很大的動能。我認為短期內,我們要處理的是需要做得更好的商業執行。我對團隊有信任與信心,他們知道該做什麼,而且會交出成果。

  • Operator

    Operator

  • Joanne Wuensch, Citi.

    Citi 的 Joanne Wuensch。

  • Joanne Wuensch - Analyst

    Joanne Wuensch - Analyst

  • Good morning and thank you so much for taking the question. The broad guidance, guidance commentary on nutrition for 2% to 4% is a nice acceleration off of the last couple of quarters. It sounds like you're getting some good momentum out of the WIC contracts. Is there an update that you can give us sort of a state of the union of what you're seeing in terms of launching some new products as well as market positioning. Thank you so much.

    早安,非常感謝讓我提問。營養品業務 2% 到 4% 的整體指引與相關評論,相較過去幾季是很不錯的加速。聽起來你們從 WIC 合約獲得了不錯的動能。能否更新一下你們所看到的整體狀況,包括新產品上市以及市場定位方面的進展?非常感謝。

  • Robert Ford - Chairman of the Board, Chief Executive Officer

    Robert Ford - Chairman of the Board, Chief Executive Officer

  • Yeah, absolutely. I think I mentioned in our first -- in our Q1 call that we were tracking according to plan, that was back in April. I'm reiterating that same message here. We remain very much on track. There's a lot of proof points here, Joanne, in terms of being able to feel confident about not only the acceleration in the second half but establishing this kind of 2% to 4% kind of range here for this business. About $125 million of sequential growth, as I said in my prepared comments. And what I liked about it as we're looking at it every single month, it was getting better.

    好的,當然可以。我想我在第一——在我們第一季電話會議時提到,我們的進度符合計畫,那是在四月。我在這裡重申同樣的訊息。我們仍然非常按計畫推進。這裡有很多可驗證的證據點,Joanne,讓我們不僅對下半年加速有信心,也對這項業務建立 2% 到 4% 這樣的區間有信心。如我在事先準備的發言中所說,約 1.25 億美元的季對季成長。而我喜歡的一點是,當我們每個月都在看數據時,它是在持續變得更好。

  • So a couple of highlights, I guess. On the pediatric side, as I said, the international portion is now back to positive growth. It actually had the highest -- our sales in international pediatric has been the highest in the last two years or so. So I think the team is doing a good job there. In U.S. pediatric, we referenced the contract -- the WIC contracts. Those are now fully baked in and we're back to market leadership after six months of very hard work out in the field. So the team has done a good job there.

    我想提幾個重點。在兒科方面,如我所說,國際部分現在已回到正成長。事實上,我們國際兒科的銷售額是過去兩年左右的最高水準。所以我認為團隊在那裡做得很好。在美國兒科方面,我們提到合約——WIC 合約。這些現在已完全反映在業績中,經過前線六個月非常辛苦的努力後,我們也回到市場領導地位。所以團隊在那裡也做得很好。

  • On the adult side, which is probably where the pricing strategy had more of an impact or at least, we expected it to have more of an impact. I think the volumes are responding very positively to that. Retail consumption of Ensure in the US is up double digits versus our exit in 2025. Of course, that's a pretty low point here. But if you look at it from a year-over-year perspective, like I said, it's one of the highest growth rates we've had in over 1.5 years from a consumption perspective.

    在成人端,這可能是定價策略影響較大、或至少我們原本預期影響較大的地方。我認為銷量對此反應非常正面。在美國,Ensure 的零售端消費量相較我們在 2025 年的期末水準呈現兩位數成長。當然,那是一個相當低的基期。但若以年對年角度來看,如我所說,從消費量的角度,這是我們超過 1.5 年以來最高的成長率之一。

  • So you've got the volume consumption now chewing through that price that we had to -- that we took in Q4. And I expect both these businesses now, adult and pediatric, to go back to a positive territory as we've worked our way through all the inventory and the new pricing.

    所以現在的消費量正在逐步消化我們——我們在第四季所採取的那次漲價。而我預期,隨著我們把所有庫存與新定價都走完,成人與兒科這兩個業務都會回到正成長區間。

  • So I think Q3 will probably be the most, I'd say, cleanest quarter. Obviously, Q4, you have a pretty big comp issue, right, which is why I -- if you look at the exit rate, we're going to be in that 2.5%, 3% if you take it on a two-year CAGR. So that's why I'm anchoring this kind of 2% to 4% trajectory.

    所以我認為第三季可能會是最——我會說最乾淨的一季。顯然,第四季你會面臨相當大的比較基期問題,對吧?這也是為什麼我——如果你看期末成長率,以兩年 CAGR 來看,我們會在 2.5%、3% 左右。所以這就是我把這條成長軌跡錨定在 2% 到 4% 的原因。

  • The new product launches are doing very well. There's obviously a lot of focus on protein, especially with GLP users, and we've been trying to offer something that's a little different, not just the protein but also protein with low/less sugar because a lot of the products that are out there have -- they taste very well, but they taste very well because there's a lot of sugar. And some of the companies that are marketing these products, they're notorious for knowing how to work with sugar.

    新產品上市表現非常好。顯然市場對蛋白質有很高的關注,特別是 GLP 使用者;我們一直嘗試提供一些更有差異化的產品,不只是蛋白質,還包括低糖/較少糖的蛋白質,因為市面上很多產品——口感很好,但口感好是因為糖很多。而有些行銷這些產品的公司,以很懂得如何運用糖而聞名。

  • So I would say we've got good momentum from the marketing messaging around high protein and low sugar. And then we've got a bunch of upcoming product launches. I think probably the ones I'm more excited about is we've got a collagen protein shake that's coming out. We'll be offering a new adult product that will have not only protein and HMB, but we're going to be adding creatinine sorry, creatine to it. So that is going to be a very strong focus, and then we'll be also launching a new infant formula in the second half using whole milk.

    所以我會說,我們在「高蛋白、低糖」的行銷訊息上取得了不錯的動能。接下來也有一系列即將上市的產品。我想我最期待的幾項是:我們將推出一款膠原蛋白奶昔。我們也會推出一款新的成人產品,不僅含蛋白質與 HMB,還會加入肌酸——抱歉,是 creatine(肌酸)。所以這會是一個非常重要的重點;此外,我們也會在下半年推出一款使用全脂牛奶的新嬰兒配方奶粉。

  • So I think that the execution here, if it's state of the union here, Joanne, is, listen, I think the team has responded well to the challenge. There are obviously things that we can continue to do better. We know what they are. We're going to continue to focus on that.

    所以如果要用「整體狀況」來形容這裡的執行,Joanne,我會說:聽著,我認為團隊對挑戰的回應很好。當然也有一些事情我們仍可以持續做得更好。我們知道那些是什麼。我們會持續聚焦在那上面。

  • But I think right now, the trajectory and the plan that we had. We're a little bit ahead of that. I'm not going to change that guidance right now based on two quarters. But you could see if we can continue to maintain this momentum and continue to surpass what our expectations were there might be an opportunity here to kind of rethink about the guidance of this business. But right now, I think we're in the right spot, and this is just about execution and developing proof points that we're moving forward and that the strategies that we put in place are reigniting the growth in this business.

    但我認為就目前而言,我們原先的軌跡與計畫。我們是稍微超前的。我不會因為兩個季度就立刻調整這個指引。但你可以看到,如果我們能持續維持這股動能,並持續超越我們原先的預期,這裡可能會有機會重新思考這項業務的指引。但目前我認為我們的位置是對的;這就是關於執行,以及建立證據點,證明我們正在向前推進,且我們所採取的策略正在重新點燃這項業務的成長。

  • Joanne Wuensch - Analyst

    Joanne Wuensch - Analyst

  • Wonderful, thank you.

    太好了,謝謝。

  • Mike Comilla - Vice President, Investor Relations

    Mike Comilla - Vice President, Investor Relations

  • Crystal, we'll take one more question, please.

    Crystal,請再讓我們接最後一個問題。

  • Operator

    Operator

  • Marie Thibault, BTIG.

    BTIG 的 Marie Thibault。

  • Marie Thibault - Analyst

    Marie Thibault - Analyst

  • Hi, good morning. Thanks so much for taking my question. I wanted to circle back here on Amulet and the left atrial appendage closure market. You certainly got a really exciting product catalyst ahead with Amulet 360, but I just want to understand what Abbott is seeing out there in the market today. Certainly, your competitors talked about some challenges they're facing. So I just want to understand sort of the appetite for left atrial appendage closure today. Thanks for taking the question.

    嗨,早安。非常感謝讓我提問。我想回到 Amulet 與左心耳封堵(LAA closure)市場這個話題。你們在 Amulet 360 上確實有一個非常令人振奮的產品催化劑即將到來,但我想了解 Abbott 目前在市場上看到的是什麼。當然,你們的競爭對手談到他們正面臨一些挑戰。所以我想了解一下,目前市場對左心耳封堵的需求/意願大概如何。謝謝讓我提問。

  • Robert Ford - Chairman of the Board, Chief Executive Officer

    Robert Ford - Chairman of the Board, Chief Executive Officer

  • Sure, Marie. I mean, this is ultimately a very attractive market, which is why we continue to make the investment. It's a $2 billion market. The competitor has a 90% market share. So to be honest with you, given the market share differences there, I will defer to our competitor to -- for more specific market growth projections here, Marie.

    當然可以,Marie。我的意思是,這最終是一個非常具吸引力的市場,這也是我們持續投入的原因。這是一個20億美元的市場。競爭對手擁有90%的市占率。所以坦白說,考量到那裡的市占差異,關於更具體的市場成長預測,我會請競爭對手來提供——Marie。

  • My focus and the team's focus here is on market share capture. I think this represents a big opportunity for us. Data and feedback from Amulet 360 has been fantastic, actually. You now have what is known as a superior product to be able to actually feel the LAA now with 360 to have a much more seamless implant experience for the physician. So I think that this is going to bode well for our EP business.

    我和團隊在這裡的重點是搶占市占率。我認為這對我們而言是一個很大的機會。來自 Amulet 360 的數據與回饋其實非常出色。你現在擁有所謂的更優越產品,透過 360 能夠實際感知 LAA,讓醫師的植入體驗更順暢無縫。所以我認為這將有利於我們的電生理(EP)業務。

  • As you know, the LAA is increasingly becoming an EP procedure. And if you think about where a lot of the growth is coming from, it's coming from the concomitant segment. And I think we're well positioned there to be able to kind of drive market share. I think this -- it's not by accident that we move this portfolio from Structural Heart into our EP business because we believe that the winning company in this space, not only have great PFA catheters, great mapping systems, great field mappers, but you also got to have a great LAA device here to be able to do that. And I think we're way ahead of our competitors from that perspective.

    如你所知,LAA 正日益成為一項電生理(EP)手術。而如果你思考許多成長來自哪裡,主要來自同時(concomitant)治療的區隔。我認為我們在那方面具備良好定位,能夠推動市占率提升。我想——我們把這個產品組合從結構性心臟(Structural Heart)移到我們的 EP 業務並非偶然,因為我們相信在這個領域的勝出者,不僅要有優秀的 PFA 導管、優秀的定位系統、優秀的場域定位(field mappers),還必須有一個優秀的 LAA 裝置才能做到這些。而從這個角度來看,我認為我們遠遠領先競爭對手。

  • So listen, I think this is an attractive market, about its future growth projections. I mean, we could probably lay out the opportunities that exist there, but my more immediate opportunity for Abbott is to be able to kind of gain market share. We're going to have an opportunity to essentially relaunch a product, you don't get a lot of opportunities like that. We'll leverage some of the lessons we've learned, and I'm pretty confident here that we'll be able to have this be a nice growth driver for us in 2027 and beyond.

    所以聽著,我認為這是一個具吸引力的市場,至於其未來的成長預測。我的意思是,我們或許可以把那裡存在的機會攤開來談,但對 Abbott 而言更立即的機會,是能夠提升市占率。我們將有機會基本上重新推出一項產品,你不會常常有這樣的機會。我們會運用一些已學到的經驗教訓,而我相當有信心,我們能讓它在 2027 年及之後成為一個不錯的成長驅動力。

  • I actually think that this idea of concomitant procedures with LAA aren't just restricted to the Electrophysiology segment. I think there's going to be opportunities in the Interventional Cardiology side also to think about. So the way we think about it is, yeah, there's an opportunity over here we're going to focus on market share. But there's -- I think there's also a market development work to happen both on the EP side but also in the Interventional side, too. So a lot of work going on there, but I'd say very excited about bringing this next-generation product to market and feel good about the market and the product we have and the team that we got.

    我其實認為,LAA 的同時(concomitant)手術這個概念不僅限於電生理(EP)領域。我認為在介入性心臟病(Interventional Cardiology)端也會有值得思考的機會。所以我們的看法是,是的,這邊有一個機會,我們會專注在市占率。但我認為同時也需要做市場開發的工作,不僅在 EP 端,也在介入端。所以那裡有很多工作在進行,但我會說,我們非常期待把這一代的下一代產品推向市場,並且對市場、我們的產品以及我們的團隊都很有信心。

  • So with that, I'll just close on the comments here since we're up on time. I'd say good progress on addressing what are these, I'd say, short-term and kind of temporary challenges that we've highlighted in January. So very good progress there. I think we're entering the second half with a lot of momentum, several of our key growth drivers. We know what they are. We know what we need to do, and that's what we're focusing on every single week and month on execution to the targets that we've set for ourselves. So my confidence remains high in that second half acceleration.

    那麼,因為時間差不多了,我就用這些評論作結。我會說,在解決我們於一月所強調的這些短期且偏暫時性的挑戰方面,已取得良好進展。所以那方面進展非常好。我認為我們帶著很強的動能進入下半年,我們有幾個關鍵的成長驅動因素。我們知道它們是什麼。我們知道需要做什麼,而我們每一週、每一個月都專注於執行,朝我們為自己設定的目標前進。所以我對下半年加速成長的信心依然很高。

  • The efforts and focus that we put on gross margin and our gross margin expansion strategy, both from a mix and cost mitigation they're having an impact, and that's allowed us to raise our full year EPS guidance, and we raised it more by the beat that we had in the second half because we believe that the sustainability of this expansion is there.

    我們在毛利率以及毛利率擴張策略上投入的努力與聚焦,無論是產品組合(mix)或成本緩解(cost mitigation)都正在產生影響,這也讓我們得以上調全年 EPS 指引;而我們上調的幅度甚至高於下半年所達成的超預期表現,因為我們相信這種擴張具有可持續性。

  • Our cash generation and cash flow management are likely going to put us ahead of our January forecast for the year, and that's going to just allow greater flexibility here for capital return. And I'm extremely excited about the pipeline that we built both for the products that we're launching and the future product launches that we're going to have over the next 24 months. I think it gives us confidence that we've got a lot of momentum that we're building is sustainable as we move into '27 and '28. So with that, I thank you for joining us today.

    我們的現金創造能力與現金流管理,很可能會讓我們全年表現優於一月的年度預測,這將使我們在資本回饋方面擁有更大的彈性。而我也對我們建立的產品管線感到非常振奮,包含我們正在推出的產品,以及未來 24 個月內將推出的產品。我認為這讓我們有信心:我們正在建立的強勁動能,隨著我們邁入 '27 與 '28 仍將具有可持續性。那麼,謝謝各位今天加入我們。

  • Mike Comilla - Vice President, Investor Relations

    Mike Comilla - Vice President, Investor Relations

  • Thank you all for your questions. This now concludes Abbott's conference call. A webcast replay of this call will be available after 11:00 AM Central Time today on our website, abbott.com. Thank you for joining us today.

    謝謝各位的提問。Abbott 的電話會議到此結束。本次電話會議的網路重播將於今日中部時間上午 11:00 之後在我們的網站 abbott.com 提供。謝謝各位今天加入我們。

  • Operator

    Operator

  • Thank you. This concludes today's conference call. Thank you for your participation. You may now disconnect. Everyone, have a wonderful day.

    謝謝。今天的電話會議到此結束。感謝各位的參與。您現在可以掛線。各位,祝您有美好的一天。